Will Panorama credit the folk who exposed Neil Woodford on Monday: here are our top 50 exposes since 2015
Tom Winnifrith Bonus Bearcast: A monkey lies down with 2 dogs and emerges covered in fleas, Vast is 'avin' a giraffe as is the FCA while St James's screws its clients
EXCLUSIVE: Ingenious SEIS fund – what are they not telling us as Nominee goes into Special Administration?
From the FCA's spreadsheet of short positions required to be disclosed to it, the following shows the shorted AIM shares with positions from 2018 and thus far in 2019 (by net short position %, those in bold not on the list at the start of 2019) – and if this position has increased (red), reduced (green) or remained unchanged (black) since last week...
AIM-listed Midatech (MTPH) is a cancer-busting company which uses its Q-Sphera technology which, according to Proative Investors, works in a different way to deliver the drug at the right time. Ah, so we have a disruptive cancer-buster…..step forward Neil Woodford, who backed the IPO back in 2014 (at 267p vs share price now just 3.4p!) and ponied up to support placings along the way. Oh dear. But it gets worse……although the PR comedy this morning makes up for it!
In this case the turd has been sugared, the pill polished but make no mistake, Midatech Pharma (MTPH) is well in the merde and that is bad news for Britain’s most conceited fund manager Neil Woodford whose funds own 20% of the equity.
I have to say I haven’t come across AIM-listed Midatech (MTPH) until now. However, with interims results just released perhaps I could get a handle on it. The problem is that the interim report has a few gaping holes in it, all of which leaves a strong sense of unease. The unease in increased when I note that the recent bailout placing (at a whopping 31% discount) showed up Woodford Investment Management as a major holder. Oh dear, not a good start….
Search ShareProphets |
Recent Comments |